GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)

Velpurisiva, Praveena; Piel, Brandon P.; Lepine, Jack; Rai, Prakash

doi:10.3390/bioengineering5040083

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)

¹,

²,

³ and

^1,4,*

Department of Biomedical Engineering and Biotechnology, University of Massachusetts, Lowell, MA 01854, USA

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

Biomolecular Characterization Lab, Core Research Facility, University of Massachusetts Lowell, Lowell, MA 01854, USA

⁴

Department of Chemical Engineering, University of Massachusetts, Lowell, MA 01854, USA

Author to whom correspondence should be addressed.

Bioengineering 2018, 5(4), 83; https://doi.org/10.3390/bioengineering5040083

Received: 17 August 2018 / Revised: 4 October 2018 / Accepted: 6 October 2018 / Published: 9 October 2018

(This article belongs to the Collection Nanoparticles for Therapeutic and Diagnostic Applications)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Glioblastoma Multiforme (GBM) is a common primary brain cancer with a poor prognosis and a median survival of less than 14 months. Current modes of treatment are associated with deleterious side effects that reduce the life span of the patients. Nanomedicine enables site-specific delivery of active pharmaceutical ingredients and facilitates entrapment inside the tumor. Polo-like kinase 1 (PLK-1) inhibitors have shown promising results in tumor cells. GSK461364A (GSK) is one such targeted inhibitor with reported toxicity issues in phase 1 clinical trials. We have demonstrated in our study that the action of GSK is time dependent across all concentrations. There is a distinct 15−20% decrease in cell viability via apoptosis in U87-MG cells dosed with GSK at low concentrations (within the nanomolar and lower micromolar range) compared to higher concentrations of the drug. Additionally, we have confirmed that PLGA-PEG nanoparticles (NPs) containing GSK have shown significant reduction in cell viability of tumor cells compared to their free equivalents. Thus, this polymeric nanoconstruct encapsulating GSK can be effective even at low concentrations and could improve the effectiveness of the drug while reducing side effects at the lower effective dose. This is the first study to report a PLK-1 inhibitor (GSK) encapsulated in a nanocarrier for cancer applications. View Full-Text

Keywords: GSK461364A; Glioblastoma Multiforme; polymeric nanoparticles; cytotoxicity; enhanced permeability and retention; polo-like kinase inhibitor; oncology; oncomedicine; U-87 MG

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
PDF-Document (PDF, 393 KiB)

Share and Cite

MDPI and ACS Style

Velpurisiva, P.; Piel, B.P.; Lepine, J.; Rai, P. GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM). Bioengineering 2018, 5, 83. https://doi.org/10.3390/bioengineering5040083

AMA Style

Velpurisiva P, Piel BP, Lepine J, Rai P. GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM). Bioengineering. 2018; 5(4):83. https://doi.org/10.3390/bioengineering5040083

Chicago/Turabian Style

Velpurisiva, Praveena, Brandon P. Piel, Jack Lepine, and Prakash Rai. 2018. "GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)" Bioengineering 5, no. 4: 83. https://doi.org/10.3390/bioengineering5040083

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

GSK461364A, a Polo-Like Kinase-1 Inhibitor Encapsulated in Polymeric Nanoparticles for the Treatment of Glioblastoma Multiforme (GBM)

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI